<html>
  <head>
    <title>form8-k.htm</title>
<!-- Licensed to: WaferGen, Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
    <div>
      <div align="center">
        <div align="center">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td colspan="5" valign="top" width="79%" style="BORDER-TOP: black 4pt double">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">UNITED
      STATES</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SECURITIES
      AND EXCHANGE COMMISSION</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">WASHINGTON,
      D.C. 20549</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: times new roman">FORM
      8-K</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CURRENT
      REPORT</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pursuant
      to Section 13 or 15(d) of</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">the
      Securities Exchange Act of 1934</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      of report (Date of earliest event reported): <font style="DISPLAY: inline; FONT-WEIGHT: bold">June 16,
      2009</font></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: times new roman">WaferGen
      Bio-systems, Inc.</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Exact
      name of registrant as specified in its charter)</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="28%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nevada</font></div>
                </td>
                <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="24%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">333-136424</font></div>
                </td>
                <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20-3699764</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="28%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State
      or other jurisdiction <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of
      incorporation)</font></font></div>
                </td>
                <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="24%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission
      <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">File
      Number)</font></font></div>
                </td>
                <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(I.R.S.
      Employer <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification
      No.)</font></font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="24%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td colspan="3" valign="top" width="53%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bayside
      Technology Center</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">46531
      Fremont Blvd.</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fremont,
      CA</font></div>
                </td>
                <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="bottom" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">94538</font></div>
                </td>
              </tr>
              <tr>
                <td colspan="3" valign="top" width="53%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Address
      of principal executive offices)</font></div>
                </td>
                <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                <td valign="top" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Zip
      Code)</font></div>
                </td>
              </tr>
              <tr>
                <td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td colspan="5" valign="top" width="79%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Registrant&#8217;s
      telephone number, including area code: <font style="DISPLAY: inline; FONT-WEIGHT: bold">(510)
      651-4450</font></font></div>
                </td>
              </tr>
              <tr>
                <td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              </tr>
              <tr>
                <td colspan="5" valign="top" width="79%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Not
      Applicable</font></div>
                </td>
              </tr>
              <tr>
                <td colspan="5" valign="top" width="79%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Former
      name or former address, if changed since last report.)</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="5" valign="top" width="79%" style="BORDER-BOTTOM: black 4px double">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Check
      the appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions (see<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>General
      Instruction A.2. below):</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings 2, serif">*</font>&#160;&#160;&#160;&#160;Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings 2, serif">*</font>&#160;&#160;&#160;&#160;Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings 2, serif">*<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font></font>Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings 2, serif">*<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font></font>Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="WIDTH: 100%" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
1.01 Entry into a Material Definitive Agreement.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>On June 16, 2009, WaferGen Bio-systems,
Inc. (the &#8220;Company&#8221;) closed a private placement offering with certain accredited
investors pursuant to which the Company sold an aggregate of 3,305,000 units at
a price of $1.25 per unit, with each unit consisting of one share of the
Company&#8217;s common stock and a warrant to purchase 30% of one share of the
Company&#8217;s common stock at an exercise price of $2.00 per whole
share.&#160;&#160;The Company sold an aggregate of 3,305,000 shares of common
stock and warrants to purchase 991,500 shares of common stock.&#160;&#160;The
aggregate gross proceeds received by the Company in the offering was
$4,131,250.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>The warrants have a term of five-years
and are subject to weighted average anti-dilution protection in the event the
Company subsequently issues its shares of common stock, or securities
convertible into shares of common stock, for a price of less than $2.00 per
share.&#160;&#160;The warrants are immediately exercisable.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>In connection with the closing of the
private placement, the Company entered into a registration rights agreement with
the investors purchasing units in the offering.&#160;&#160;The registration
rights agreement requires that the Company prepare and file with the Securities
and Exchange Commission (the &#8220;SEC&#8221;) a registration statement on Form S-1
covering the resale of the shares of common stock issued in the offering as well
as the shares of common stock issuable upon exercise of the warrants issued in
the offering (collectively, the &#8220;Registrable Securities&#8221;).&#160;&#160;The
registration rights agreement provides certain deadlines for the filing and
effectiveness of the registration statement, including that the registration
statement be declared effective by the SEC within 90 days after such
registration statement has been filed with the SEC (or 120 days in the event
that the registration statement is subject to a review by the
SEC).&#160;&#160;If the Company is unable to comply with these deadlines with
respect to an amount of Registrable Securities equal to at least one-third of
the Company&#8217;s outstanding shares held by non-affiliates of the Company (the
&#8220;Initial Shares&#8221;), then the Company will be required to pay as partial
liquidated damages to the investors a cash sum equal to 1% of any unregistered
Initial Shares for every month in which such registration statement has not been
filed or declared effective, as applicable, up to maximum liquidated damages of
5% of each investor&#8217;s aggregate investment amount.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>The investors in the private placement
offering include Alnoor Shivji, the Company&#8217;s Chairman, President and Chief
Executive Officer, who purchased 800,000 units in the offering.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>The Company retained a selling agent in
connection with the private placement offering.&#160;&#160;Pursuant to the terms
of the selling agent agreement, the Company paid the selling agent a cash
commission of approximately $160,000, and the Company has agreed to issue the
selling agent warrants to purchase 128,205 shares of common
stock.&#160;&#160;The warrants to be issued to the selling agent will have
substantially the same terms as the warrants issued to the investors in the
private placement offering.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Item 3.02 Unregistered Sales of
Equity Securities.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>The information in Item 1.01 above is
incorporated into this Item 3.02 by reference.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>The issuances of securities as
described in Item 1.01 are exempt from the registration requirements of the
Securities Act of 1933, as amended, pursuant to Section&#160;4(2) thereof and
Rule 506 of Regulation D thereunder.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Item 5.02 Departure of Directors or
Principal Officers; Election of Directors; Appointment of Principal
Officers.</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>On June 17, 2009, the Company entered
into employment separation agreements with each of Amjad Huda,
the&#160;&#160;former Chief Financial Officer and Treasurer of the Company, and
Victor Joseph, the former Chief Technical Officer and Secretary of the
Company.&#160;&#160;Pursuant to the separation agreements, Mr. Huda&#8217;s and Mr.
Joseph&#8217;s employment with the Company ended on June 17, 2009.&#160;&#160;The
Company will pay each of Mr. Huda and Mr. Joseph severance in the amount of
$306,250, less applicable withholdings, payable in the form of salary
continuation over 14 months in accordance with the Company&#8217;s regular payroll
practices.&#160;&#160;All stock options granted to Mr. Huda and Mr. Joseph
pursuant to the Company&#8217;s stock incentive plans have vested in connection with
their terminations of employment, and each of Mr. Huda and Mr. Joseph will have
two years to exercise such stock options.&#160;&#160;The <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Company
will pay the premiums for COBRA medical coverage for Mr. Huda and Mr. Joseph
until the earlier of the two-year anniversary of the separation date or the date
Mr. Huda or Mr. Joseph, as the case may be, become covered under another
employer&#8217;s group health plan.&#160;&#160;Mr. Huda and Mr. Joseph each provided a
release of claims in favor of the Company, and the Company, in turn, provided
each of Mr. Huda and Mr. Joseph a release of claims.</font></font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div style="WIDTH: 100%" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
        <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
      </div>
    </div><br>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 18pt"></font>In connection with the terminations of
their employment, Mr. Huda and Mr. Joseph also agreed that, during the period
commencing on the date of separation and ending on the one year anniversary of
the date of separation, they will not transfer or sell any shares of the
Company&#8217;s common stock held by them after the date of their separation, subject
to certain exceptions, including the following: (i) beginning seven months after
the separation date and ending nine months after the separation date, each of
Mr. Huda and Mr. Joseph shall be entitled to sell in open market or otherwise
through or reportable on the over-the-counter market or any stock exchange
(&#8220;Market Transactions&#8221;) on each trading day during such three-month period an
aggregate number of shares of the Company&#8217;s common stock of no more than 15% of
the average daily volume of shares of the Company&#8217;s common stock traded over the
counter or on any stock market, as the case may be, during the three month
period from September 1, 2009 through November 30, 2009 (the &#8220;ADV&#8221;); and (ii)
beginning on the first day after nine months following the separation date and
ending on the one year anniversary of the separation date, each of Mr. Huda and
Mr. Joseph shall be entitled to sell in Market Transactions on each trading day
during such three-month period an aggregate number of shares of the Company&#8217;s
common stock of no more than 20% of the ADV.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            <td align="left" colspan="2" valign="middle" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.9pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WaferGen
      Bio-systems, Inc.</font></div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
      June 17, 2009</font></div>
            </td>
            <td align="left" valign="top" width="4%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div>
            </td>
            <td align="left" valign="middle" width="34%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
      Alnoor Shivji</font></div>
            </td>
          </tr>
          <tr>
            <td valign="middle" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            <td valign="middle" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="34%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Alnoor
      Shivji</font></div>
            </td>
          </tr>
          <tr>
            <td valign="middle" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            <td valign="middle" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="34%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chairman,
      President and Chief Executive
Officer</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center">3<br></div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="2" width="100%">
    </div><br></body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8-k.htm", "description": "FORM 8-K 6/18/09", "secsgml_size_bytes": 31324}]
{"company-data": {"conformed-name": "WaferGen Bio-systems, Inc.", "cik": "0001368993", "assigned-sic": "3826", "irs-number": "203699764", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-53252", "film-number": "09898782"}, "business-address": {"street1": "BAYSIDE TECHNOLOGY CENTER", "street2": "46571 FREMONT BLVD.", "city": "FREMONT", "state": "CA", "zip": "94538", "phone": "(510) 651-4450"}, "mail-address": {"street1": "BAYSIDE TECHNOLOGY CENTER", "street2": "46571 FREMONT BLVD.", "city": "FREMONT", "state": "CA", "zip": "94538"}, "former-company": {"former-conformed-name": "La Burbuja Cafe, Inc.", "date-changed": "20060714"}}
form8-k.htm
UNITED
      STATES
SECURITIES
      AND EXCHANGE COMMISSION
WASHINGTON,
      D.C. 20549
FORM
      8-K
CURRENT
      REPORT
Pursuant
      to Section 13 or 15(d) of
the
      Securities Exchange Act of 1934
Date
      of report (Date of earliest event reported):
June 16,
      2009
WaferGen
      Bio-systems, Inc.
(Exact
      name of registrant as specified in its charter)
Nevada
333-136424
20-3699764
(State
      or other jurisdiction
of
      incorporation)
(Commission
File
      Number)
(I.R.S.
      Employer
Identification
      No.)
Bayside
      Technology Center
46531
      Fremont Blvd.
Fremont,
      CA
94538
(Address
      of principal executive offices)
(Zip
      Code)
Registrant's
      telephone number, including area code:
(510)
      651-4450
Not
      Applicable
(Former
      name or former address, if changed since last report.)
Check
      the appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions (see
General
      Instruction A.2. below):
*
Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)
*
Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)
*
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))
*
Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))
1
Item
1.01 Entry into a Material Definitive Agreement.
On June 16, 2009, WaferGen Bio-systems,
Inc. (the "Company") closed a private placement offering with certain accredited
investors pursuant to which the Company sold an aggregate of 3,305,000 units at
a price of $1.25 per unit, with each unit consisting of one share of the
Company's common stock and a warrant to purchase 30% of one share of the
Company's common stock at an exercise price of $2.00 per whole
share.  The Company sold an aggregate of 3,305,000 shares of common
stock and warrants to purchase 991,500 shares of common stock.  The
aggregate gross proceeds received by the Company in the offering was
$4,131,250.
The warrants have a term of five-years
and are subject to weighted average anti-dilution protection in the event the
Company subsequently issues its shares of common stock, or securities
convertible into shares of common stock, for a price of less than $2.00 per
share.  The warrants are immediately exercisable.
In connection with the closing of the
private placement, the Company entered into a registration rights agreement with
the investors purchasing units in the offering.  The registration
rights agreement requires that the Company prepare and file with the Securities
and Exchange Commission (the "SEC") a registration statement on Form S-1
covering the resale of the shares of common stock issued in the offering as well
as the shares of common stock issuable upon exercise of the warrants issued in
the offering (collectively, the "Registrable Securities").  The
registration rights agreement provides certain deadlines for the filing and
effectiveness of the registration statement, including that the registration
statement be declared effective by the SEC within 90 days after such
registration statement has been filed with the SEC (or 120 days in the event
that the registration statement is subject to a review by the
SEC).  If the Company is unable to comply with these deadlines with
respect to an amount of Registrable Securities equal to at least one-third of
the Company's outstanding shares held by non-affiliates of the Company (the
"Initial Shares"), then the Company will be required to pay as partial
liquidated damages to the investors a cash sum equal to 1% of any unregistered
Initial Shares for every month in which such registration statement has not been
filed or declared effective, as applicable, up to maximum liquidated damages of
5% of each investor's aggregate investment amount.
The investors in the private placement
offering include Alnoor Shivji, the Company's Chairman, President and Chief
Executive Officer, who purchased 800,000 units in the offering.
The Company retained a selling agent in
connection with the private placement offering.  Pursuant to the terms
of the selling agent agreement, the Company paid the selling agent a cash
commission of approximately $160,000, and the Company has agreed to issue the
selling agent warrants to purchase 128,205 shares of common
stock.  The warrants to be issued to the selling agent will have
substantially the same terms as the warrants issued to the investors in the
private placement offering.
Item 3.02 Unregistered Sales of
Equity Securities.
The information in Item 1.01 above is
incorporated into this Item 3.02 by reference.
The issuances of securities as
described in Item 1.01 are exempt from the registration requirements of the
Securities Act of 1933, as amended, pursuant to Section 4(2) thereof and
Rule 506 of Regulation D thereunder.
Item 5.02 Departure of Directors or
Principal Officers; Election of Directors; Appointment of Principal
Officers.
On June 17, 2009, the Company entered
into employment separation agreements with each of Amjad Huda,
the  former Chief Financial Officer and Treasurer of the Company, and
Victor Joseph, the former Chief Technical Officer and Secretary of the
Company.  Pursuant to the separation agreements, Mr. Huda's and Mr.
Joseph's employment with the Company ended on June 17, 2009.  The
Company will pay each of Mr. Huda and Mr. Joseph severance in the amount of
$306,250, less applicable withholdings, payable in the form of salary
continuation over 14 months in accordance with the Company's regular payroll
practices.  All stock options granted to Mr. Huda and Mr. Joseph
pursuant to the Company's stock incentive plans have vested in connection with
their terminations of employment, and each of Mr. Huda and Mr. Joseph will have
two years to exercise such stock options.  The
Company
will pay the premiums for COBRA medical coverage for Mr. Huda and Mr. Joseph
until the earlier of the two-year anniversary of the separation date or the date
Mr. Huda or Mr. Joseph, as the case may be, become covered under another
employer's group health plan.  Mr. Huda and Mr. Joseph each provided a
release of claims in favor of the Company, and the Company, in turn, provided
each of Mr. Huda and Mr. Joseph a release of claims.
2
In connection with the terminations of
their employment, Mr. Huda and Mr. Joseph also agreed that, during the period
commencing on the date of separation and ending on the one year anniversary of
the date of separation, they will not transfer or sell any shares of the
Company's common stock held by them after the date of their separation, subject
to certain exceptions, including the following: (i) beginning seven months after
the separation date and ending nine months after the separation date, each of
Mr. Huda and Mr. Joseph shall be entitled to sell in open market or otherwise
through or reportable on the over-the-counter market or any stock exchange
("Market Transactions") on each trading day during such three-month period an
aggregate number of shares of the Company's common stock of no more than 15% of
the average daily volume of shares of the Company's common stock traded over the
counter or on any stock market, as the case may be, during the three month
period from September 1, 2009 through November 30, 2009 (the "ADV"); and (ii)
beginning on the first day after nine months following the separation date and
ending on the one year anniversary of the separation date, each of Mr. Huda and
Mr. Joseph shall be entitled to sell in Market Transactions on each trading day
during such three-month period an aggregate number of shares of the Company's
common stock of no more than 20% of the ADV.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
WaferGen
      Bio-systems, Inc.
Date:
      June 17, 2009
By:
/s/
      Alnoor Shivji
Alnoor
      Shivji
Chairman,
      President and Chief Executive
Officer
3